ストックスクリーナーアプリを入手
31.15
1.80%
-0.57
前日終値:
$31.72
開ける：
$31.58
24時間の取引高:
837.70K
Relative Volume:
0.54
時価総額：
$5.01B
収益：
$803.07M
当期純損益:
$-358.81M
株価収益率:
-12.77
EPS:
-2.44
ネットキャッシュフロー:
$-374.21M
1週間 パフォーマンス:
-5.35%
1か月 パフォーマンス:
-0.64%
6か月 パフォーマンス:
-23.75%
1年 パフォーマンス:
-28.14%
1日の値動き範囲:
$30.80
$31.58
1週間の範囲:
$30.80
$33.76
52週間の値動き範囲:
$30.23
$52.34
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
名前
Ionis Pharmaceuticals Inc
セクター
電話
(760) 931-9200
住所
2855 GAZELLE COURT, CARLSBAD, CA
IONS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
31.15 | 5.01B | 803.07M | -358.81M | -374.21M | -2.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-02 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | 再開されました | Jefferies | Buy |
| 2024-06-14 | アップグレード | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-10-23 | アップグレード | BofA Securities | Underperform → Neutral |
| 2023-09-29 | 開始されました | Raymond James | Strong Buy |
| 2023-07-31 | アップグレード | Citigroup | Neutral → Buy |
| 2023-06-07 | 再開されました | Piper Sandler | Overweight |
| 2023-05-04 | アップグレード | Citigroup | Sell → Neutral |
| 2023-03-21 | 開始されました | Bernstein | Underperform |
| 2022-12-21 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | 再開されました | Morgan Stanley | Overweight |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
| 2022-03-31 | 再開されました | Piper Sandler | Overweight |
| 2022-03-01 | 開始されました | Citigroup | Sell |
| 2022-03-01 | 開始されました | Guggenheim | Buy |
| 2022-02-01 | ダウングレード | BofA Securities | Buy → Underperform |
| 2021-12-14 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | アップグレード | UBS | Sell → Neutral |
| 2021-03-01 | アップグレード | Barclays | Underweight → Equal Weight |
| 2020-12-16 | 開始されました | UBS | Sell |
| 2020-12-15 | アップグレード | Cowen | Market Perform → Outperform |
| 2020-09-14 | 再開されました | JP Morgan | Neutral |
| 2020-09-02 | 開始されました | The Benchmark Company | Hold |
| 2020-06-01 | 再開されました | Oppenheimer | Outperform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-12-13 | 開始されました | Oppenheimer | Outperform |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-11-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | 繰り返されました | Stifel | Hold |
| 2018-08-07 | 繰り返されました | Stifel | Hold |
| 2018-05-08 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2017-10-06 | 再開されました | Goldman | Sell |
| 2017-08-17 | 開始されました | Evercore ISI | Outperform |
| 2017-08-09 | 繰り返されました | Stifel | Hold |
| 2017-03-10 | ダウングレード | Goldman | Neutral → Sell |
| 2016-12-28 | 繰り返されました | BMO Capital Markets | Outperform |
| 2016-12-27 | 繰り返されました | Leerink Partners | Mkt Perform |
すべてを表示
Ionis Pharmaceuticals Inc (IONS) 最新ニュース
RNA Biotechs: Current State And Outlook - Seeking Alpha
IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi - MSN
Ionis and Sobi agree on olezarsen commercialisation - Yahoo
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. - BioSpace
Ionis licenses olezarsen to Sobi for global reach By Investing.com - Investing.com South Africa
Ionis Partners With Sobi to Commercialize Familial Chylomicronemia Syndrome Treatment Outside US - Marketscreener.com
Ionis Expands Partnership With SOBI To Include Olezarsen Commercialization Outside The U.S. - Marketscreener.com
Ionis licenses olezarsen to Sobi for global reach - Investing.com
First-Ever FCS Treatment: Ionis Expands Global Reach with Major Partnership Deal - StockTitan
Is Ionis Pharmaceuticals, Inc. (IONS) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
12 Most Promising Biotech Stocks According to Wall Street Analysts - Insider Monkey
Ionis Pharmaceuticals’ SWOT analysis: RNA pioneer’s stock faces pivotal year - Investing.com
Ionis Rings the Opening Bell - Nasdaq
Ionis Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting - GlobeNewswire Inc.
Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S - Simply Wall St
Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report? - Yahoo Finance Australia
Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Ionis Pharma - Barchart
Multiple System Atrophy Market to Reach New Heights in Growth - openPR
Familial Chylomicronemia Syndrome Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Spinocerebellar Ataxias Pipeline 2025: Therapies, MOA - openPR
Ionis Pharmaceuticals at UBS Virtual CNS Day: Neurology Pipeline Insights By Investing.com - Investing.com UK
Opinion: Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx and Neuren - BioSpace
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe - MSN
Retinitis Pigmentosa Pipeline 2024: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Biogen, Neurotech, Ionis Pharma, Nacuity Pharma, Allegro Ophthalmics - Barchart
Ionis Pharmaceuticals CEO Monia sells $4,524 in stock By Investing.com - Investing.com Australia
Charles Schwab Investment Management Inc. Purchases 38,420 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World
Chief Executive Officer Monia Brett P sold $4,525 worth of shares (140 units at $32.32), decreasing direct ownership by 0.08% to 180,980 units (SEC Form 4) - Quantisnow
Ionis Pharmaceuticals CEO Monia sells $4,524 in stock - Investing.com India
Ionis Gets Tryngolza Launch Cash From Ono Via Sapablursen License - Citeline
Ionis Pharmaceuticals at Barclays Conference: Strategic Growth and Partnerships By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - AOL
Ono earmarks $940m to gain rare blood cancer therapy from Ionis - Yahoo
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal - AOL
Ono partners with Ionis for sapablursen - The Pharma Letter
Ono pays $280M to license Ionis rare disease drug - BioPharma Dive
Oppenheimer maintains Outperform on Ionis, $78 target By Investing.com - Investing.com UK
Ionis out licenses blood disorder therapy to Ono in a deal worth up to $940M - MSN
Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono - Zacks Investment Research
Ionis Pharmaceuticals Enters Global License Agreement With Ono Pharmaceutical for Sapablursen - Marketscreener.com
Jones Financial Companies Lllp Has $326,000 Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Cut to $47.00 by Analysts at JPMorgan Chase & Co. - Defense World
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera - Quantisnow
Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera - Bluefield Daily Telegraph
What Analysts Are Saying About Ionis Pharmaceuticals Stock - Benzinga
Massive $940M Deal: Ionis Partners with Ono on Breakthrough Blood Cancer Treatment - StockTitan
When the Price of (IONS) Talks, People Listen - Stock Traders Daily
AstraZeneca and Ionis win EU approval for ATTR polyneuropathy - Yahoo Finance
EU clears AZ, Ionis' Wainzua for ATTR polyneuropathy - pharmaphorum
Ionis Pharmaceuticals Says Transthyretin-Mediated Amyloidosis Treatment Gets Approval in Europe - Marketscreener.com
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy - Quantisnow
Ionis Pharmaceuticals Inc (IONS) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):